On May 6, 2021, PILMA released the following statement on the far reaching negative impacts of the U.S. signing on to the WTO TRIPS waiver. Download the statement here. May 6, 2021 The U.S. Trade Representative’s decision to support waiving intellectual property protections for the COVID-19 vaccine is a danger to worldwide health and security, […]
On March 1, 2021, General President of SMART and PILMA Chairman Joseph Sellers, Jr. sent the following letter to the Acting U.S. Trade Representative Maria L. Pagan urging continued protections of intellectual property: View letter from President Sellers. View letter from PILMA Executive Director Timothy Dickson. March 1, 2021Maria L. PaganActing United States Trade Representative600 […]
Last year, PILMA in collaboration with union health care and benefits expert Randy DeFrehn released a report titled “An Understanding and Implications of the Cost Drivers in the Drug Supply Chain.” PILMA combined DeFrehn’s findings with data from a new report by Berkeley Research Group to extrapolate on the original report and provide insight into which entities in the supply chain are receiving an increasing share of revenue from prescription medicines.
On January 16, 2019, Eric Dean, General President of the International Association of Bridge, Structural, Ornamental and Reinforcing Iron Workers and Chairman of PILMA issued the following statement on legislative proposals that would negatively impact innovation and jobs. View the statement in PDF. The biopharmaceutical industry supports more than 4.7 million American jobs. Significant investment in capital […]
December 13, 2018 Today, PILMA in partnership with the Institute for Construction Economic Research (ICERES) released a first of its kind report quantifying the economic impact of the partnership between the building trades unions and the biopharmaceutical industry. Main takeaways include: The partnership between skilled craft unions and biopharmaceutical companies helped drive $14 billion in construction investment […]
On October 25, 2018, PILMA released the following statement in response to President Trump’s speech at the Department of Health and Human Services. The statement follows a previously adopted PILMA Resolution on Price Controls. View the statement in PDF. The labor unions and biopharmaceutical companies of the Pharmaceutical Industry Labor-Management Association (PILMA) have a longstanding […]